|
|
|
| Clinical effect of low molecular weight heparin for fetol growth restriction Pregnant women and perinatal outcome |
| WU Guan |
| Department of Gynaecology and Obstetrics,Maternal and Child Health Hospital of Yangchun City in Guangdong Province,Yangchun 529600,China |
|
|
|
|
Abstract ObjectiveTo investigate the clinical effect of low molecular weight heparin for fetal growth restriction pregnant women and perinatal outcome.Methods96 cases of FGR pregnant women in our hospital from November 2015 to July 2016 were randomly divided into research group and control group,48 cases in each group.The control group was treated with maternal underlying diseases,early strengthening of diet nutrition,while the research group was treated with low molecular weight heparin based on the treatment control group.The height of the uterus and fetal growth,amniotic fluid index,and biophysical score of pregnant women,and gestational age,weight and asphyxia of newborn,platelet count and coagulation function index changes of two groups were compared.ResultsAfter treatment,the height of the uterus, the growth value of head circumference,abdominal circumference,biparietal diameter and femur length of research group newborns were higher than those of control group(P＜0.05).The amniotic fluid index,and biophysical score of research group were(13.79±1.46)cm,(9.93±0.58)points respectively,which were better than those of control group of(11.41±1.50)cm, (9.26±0.42)points(P＜0.05).The newborns gestational age,weight of research group were better than those of control group (P＜0.05).Newborns asphyxia rate of research group was lower than that of control group(P＜0.05).The platelet count and coagulation function index of two groups had no significant difference(P＞0.05).ConclusionLow molecular weight heparin has exact effect for FGR.The weight of newborn is improved,and low molecular weight heparin could improve placental blood circulation,promote fetal growth,reduce the incidence of neonatal asphyxia.It′s worthy of wildly used.
|
|
|
|
|
|
| [1] |
乔文俊.低分子肝素钠在胎儿生长受限治疗中的应用研究[J].中国综合临床，2014，3（3）：332-333.
|
| [2] |
杨鹃，李聪，杨永华.低分子肝素钠早期干预治疗FGR的临床研究[J].中国医药科学，2014，4（23）：63-65.
|
| [3] |
李玲玲，张龑.低分子肝素对胎儿生长受限患者胎盘超微结构及血管内皮生长因子表达的影响[J].中国妇产科临床杂志，2012，13（6）：440-442.
|
| [4] |
陈晖，姜立新，雷艳爱.低分子肝素治疗胎儿生长受限对孕妇血栓前状态及新生儿结局的影响[J].国际医药卫生导报，2013，19（17）：2669-2671.
|
| [5] |
段颜，延英，余江.小剂量低分子肝素治疗胎儿生长受限20例观察[J].山东医药，2013，53（15）：94-95.
|
| [6] |
雷艳爱，陈晖，刘杏仙，等.低分子肝素联合护理干预在胎儿生长受限中的应用[J].齐鲁护理杂志，2015，21（11）：79-81.
|
| [7] |
章茜，姜纬.低分子肝素联合低分子右旋糖酐治疗胎儿宫内生长受限的效果观察[J].山东医药，2014，54（45）：73-74.
|
| [8] |
张丽，易箐，崔霞.低分子肝素抗凝治疗对子痫前期产妇血清MMP-9，胱抑素C水平的影响[J].中国医学创新，2015，12（32）：23-26.
|
| [9] |
吴婷，罗力冰.低分子肝素对胎儿生长受限孕妇血栓前状态的改善作用[J].中国临床研究，2015，28（3）：353-355.
|
| [10] |
朱薏，路妍妍，田耕.丹参注射液与低分子肝素治疗胎儿生长受限的临床疗效比较[J].现代医院，2016，16（4）：483-485.
|
| [11] |
芮璨，宋学静，龙伟.低分子肝素治疗子痫前期合并胎儿生长受限对妊娠结局的影响[J].江苏医药，2015，41（16）：1887-1890.
|
| [12] |
向罗珺，骆祚兰，肖延龄，等.低分肝素治疗早发型和晚发型胎儿生长受限的临床应用[J].现代仪器与医疗，2016，22（1）：34-36.
|
| [13] |
邓小梅，欧璐，向冬梅，等.低分子肝素治疗胎儿生长受限的临床效果及对新生儿结局的影响[J].中国现代医生，2015，53（17）：43-45.
|
|
|
|
